Synonyms: BCX-4430 | BCX4430 | Immucillin-A
Compound class:
Synthetic organic
Comment: Galidesivir (BCX4430) is an adenosine analogue and broad-spectrum antiviral agent [3]. It was originally developed as a treatment for hepatitis C infection, but has subsequently demonstrated activity against Ebola, Marburg and Zika [1] viruses, and was most recently evaluated for potential to treat SARS-CoV-2 infection (COVID-19). Mechanistically it inhibits the virus' RNA-dependent RNA-polymerase (RdRp), that acts as a nonobligate RNA chain terminator.
|
|
Bioactivity Comments |
Antiviral activity of galidesivir (BCX4430) against Zika virus in infected human cells in vitro (EC50 ~4 μg/ml) [1]. Demonstrates weak antiviral activities (in vitro) against SARS-CoV (EC50 = 57.7 μM) and MERS-CoV (EC50 = 68.4 μM), but does not inhibit SARS-CoV-2 viral replication at concentrations below 100 μM [2]. |